MENLO PARK, Calif.–(BUSINESS WIRE)–Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced its emergence from stealth and upcoming presentation of first-in-human clinical data at the American Thoracic Society (ATS) 2025 International Conference, May 16-21 in San Francisco. The company’s BREATHE 1&2 feasibility studies will be presented as a late-breaking abstract on Monday, May 19.